Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Tamibarotene||Am 80|SY-1425|TOS-80T|INNO-507||Tamibarotene (SY-1425) is a synthetic retinoid that activates retinoic acid receptor signaling, which in turn induces differentiation and apoptosis in leukemia cells (PMID: 17925887, PMID: 30093681).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||acute promyelocytic leukemia||not applicable||Tamibarotene||Phase III||Actionable||In a Phase III trial (JALSG-APL204), treatment with Tamibarotene (SY-1425) resulted in a greater relapse-free survival (RFS) when compared to treatment with Tretinoin, demonstrating a 7-year RFS of 93% (n=134) versus 84% (n=135), and a 7-year RFS of 89% (n=26) vs 62% (n=26) in high risk patients, while overall survival after randomization did not differ between the two treatment groups after 7 years, 97% versus 96%, respectively (PMID: 30093681).||30093681|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02807558||Phase II||Azacitidine + Tamibarotene Tamibarotene||A Biomarker-Directed Phase 2 Trial of SY-1425 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome||Active, not recruiting||USA||1|